Repository

Publications

Drug-Resistant Cholangiocarcinoma Cell Lines for Therapeutic Evaluation of Novel Drugs

Delgado-Calvo K, Lozano E, Briz O, Cives-Losada C, Marin JJG, Macias RIR
Molecules. 2025 Jul 21;30(14):3053. doi: 10.3390/molecules30143053
2025 
Result from  

A novel naphthoquinone compound triggers DNA damage-induced apoptosis on cholangiocarcinoma through upregulation of BAX

Bulut G, Kayis M, Gezer D, Gokmen Z, Adiguzel Z, Raggi C, Ulukaya E.
Med Oncol. 2025 Jul 20;42(8):354. doi: 10.1007/s12032-025-02927-7
2025 
Result from  

Gut-to-Bile transfer of microbially amidated minor bile acids in patients with hepatopancreatobiliary disorders

Temprano AG, Romero MR, Ghallab A, Llera L, Macias RIR, van Eijk HM, Rullán M, Urman J, Ay Ü, Lenicek M, Hengstler JG, Neumann UP, Berasain C, Avila MA, Olde Damink SWM, Monte MJ, Marin JJG, Schaap FG.
Hepatology. 2025 Jun 23. doi: 10.1097/HEP.0000000000001441
2025 
Result from  
OA Funded by  

Negative impact of corticosteroid use on outcome in patients with advanced BTCs treated with cisplatin, gemcitabine, and durvalumab: A large real-life worldwide population

Prinzi FL, Salani F, Camera S, Rizzato MD, Saborowski A, Antonuzzo L, Rossari F, Satake T, Peeters F, Pressiani T, Lucchetti J, Kim JW, Abidoye O, Rapposelli IG, Gallio C, Tamberi S, Finkelmeier F, Giordano G, Chiara P, Chon HJ, Braconi C, Qaisar A, Pastorino A, Castet F, Tamburini E, Yoo C, Parisi A, Diana A, Scartozzi M, Prager GW, Avallone A, Schirripa M, Kim IH, Perkhofer L, Oneda E, Verrico M, Couto N, Adeva J, Chan SL, Spinelli GP, Personeni N, Garajova I, Rodriquenz MG, Leo S, Alvim CM, Roque R, Polito MG, Di Giacomo E, Farinea G, Bartalini L, Grelli G, De Rosa A, Lavacchi D, Ikeda M, Dekervel J, Niger M, Balsano R, Tonini G, Kang M, Tesini G, Boccaccino A, Himmelsbach V, Landriscina M, Djaballah SA, Bekaii-Saab T, Fornaro L, Masi G, Vogel A, Lonardi S, Rimini M, Rimassa L, Casadei-Gardini A.
Int J Cancer. 2025 Jul 11. doi: 10.1002/ijc.70009
2025 
Result from  

The impact of molecular alterations in patients with advanced biliary tract cancer receiving cisplatin, gemcitabine and durvalumab: a large real-life worldwide population

Rimini M, Fornaro L, Lo Prinzi F, Rizzato MD, Saborowski A, Antonuzzo L, Rossari F, Satake T, Peeters F, Vivaldi C, Pressiani T, Lucchetti J, Kim JW, Abidoye O, Rapposelli IG, Tamberi S, Finkelmeier F, Giordano G, Nichetti F, Jae Chon H, Braconi C, Qaisar A, Pirrone C, Castet F, Tamburini E, Yoo C, Parisi A, Diana A, Scartozzi M, Prager GW, Avallone A, Corallo S, Schirripa M, Kim IH, Perkhofer L, Oneda E, Verrico M, Adeva J, Chan SL, Spinelli GP, Personeni N, Garajova I, Rodriquenz MG, Leo S, Alvim CM, Roque R, Farinea G, Salani F, De Rosa A, Lavacchi D, Camera S, Ikeda M, Dekervel J, Niger M, Balsano R, Tonini G, Kang M, Bekaii-Saab T, Esposito L, Boccaccino A, Himmelsbach V, Landriscina M, Djaballah SA, Zanuso V, Malapelle U, Pepe F, Masi G, Vogel A, Lonardi S, Rimassa L, Casadei-Gardini A.
J Natl Cancer Inst. 2025 Jul 3:djaf155. doi: 10.1093/jnci/djaf155
2025 
Result from  
Join the Action
JOIN